Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

NCT03603314 is registered in ClinicalTrials.gov with Sensorion as lead sponsor.

NCT NCT03603314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03603314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Lead sponsor
Sensorion
Phase
Phase 2/3
Overall status
Completed
Start date
February 15, 2019
Completion date
January 12, 2022
Enrollment
115 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

severe sudden sensorineural hearing loss